TSLP His Tag Protein: The "Alarm Initiator" of Type 2 Immune Response

I. Overview: Molecular Characteristics, Origin, and Signaling Cascade

TSLP is a cytokine primarily secreted by barrier epithelial cells, and its expression and release serve as an early alarm signal after epithelial cells perceive environmental threats.

Molecular Structure and Induced Expression:

TSLP exists in two forms: the long form exhibits full cytokine activity and is the main driver of inflammation; the physiological function of the short form remains unclear but may play a role in homeostasis. Recombinant TSLP His Tag protein typically mimics the activity of the long form.

Primary sources: Keratinocytes in the skin, airway epithelial cells, and intestinal epithelial cells are its main producers. Various stimuli, including IL-4, IL-13, TNF-α, viral double-stranded RNA, proteases (e.g., Der p1 from house dust mites), and physical barrier disruption, can strongly induce its expression.

TSLP Receptor Complex:

TSLP acts through a unique heterodimeric receptor:

TSLP receptor chain: Shared with the IL-7Rα chain (CD127).

TSLP-specific chain: A protein homologous to the common γ chain of cytokine receptors.

This receptor is primarily expressed on myeloid cells, particularly dendritic cells, mast cells, eosinophils, basophils, and some B cells and CD4⁺ T cells.

Function of the His Tag:

The fused His tag enables efficient nickel-column affinity purification of the protein, ensuring high purity and activity of the recombinant protein, facilitating in vitro functional experiments, receptor binding analyses, and animal model studies.

II. Core Mechanism: Driving the Cascade of Type 2 Immunity

The core function of TSLP is to serve as a bridge connecting epithelial injury with adaptive type 2 immune responses, forming a clear amplification loop.

1. "Educating" Dendritic Cells Toward a Pro-Inflammatory Phenotype

TSLP acts on immature or quiescent dendritic cells, endowing them with a unique "TSLP-DC" phenotype.

These DCs upregulate costimulatory molecules (e.g., OX40L) but do not produce significant amounts of IL-12, distinguishing them from DCs that drive Th1 differentiation.

TSLP-DCs migrate to draining lymph nodes and, through antigen presentation and signals like OX40L, selectively drive naïve CD4⁺ T cells to differentiate into Th2 cells producing IL-4, IL-5, and IL-13, while suppressing regulatory T cell development.

2. Direct Activation of Innate Immune Effector Cells

Activation of type 2 innate lymphoid cells: TSLP can directly stimulate ILC2s to produce large amounts of IL-5 and IL-13, rapidly amplifying type 2 inflammation in the early stages of allergy, independent of T cells.

Enhancing mast cell and eosinophil function: TSLP can improve the survival, activation, and mediator release capabilities of these cells.

3. Signaling Pathway: Core Driven by JAK-STAT

Upon binding to its receptor, TSLP primarily activates JAK1 and JAK2 kinases.

The phosphorylated receptor recruits and activates STAT5 (and STAT3). STAT5 dimers translocate to the nucleus, driving the expression of genes related to Th2 polarization and type 2 inflammation.

It also activates auxiliary pathways like PI3K/Akt.

4. Synergistic Effects with IL-25 and IL-33

At barrier sites, TSLP is often produced alongside IL-25 and IL-33 by epithelial cells, collectively referred to as "epithelial-derived alarmins."

These three act synergistically but with distinct emphases: TSLP focuses more on guiding adaptive Th2 immunity through DCs, while IL-25 and IL-33 more directly and rapidly activate ILC2s. Together, they form a robust type 2 immune defense network against barrier disruption.

III. Downstream Applications: Linking Epithelial Barrier Diseases to Targeted Therapies

Abnormal activation of TSLP signaling is a common starting point for many chronic inflammatory diseases, making it a highly valuable intervention target.

1. Allergic and Inflammatory Diseases

Severe asthma (especially the type 2 inflammatory phenotype): Airway epithelial cells produce TSLP in response to allergens and other stimuli, driving airway eosinophilic inflammation, mucus hypersecretion, and airway hyperresponsiveness. The monoclonal antibody Tezepelumab, targeting TSLP, has been approved for treating severe asthma. Its uniqueness lies in significantly reducing acute exacerbations regardless of baseline eosinophil counts, demonstrating the broad-spectrum potential of targeting upstream "alarm initiators."

Atopic dermatitis: Skin barrier defects lead to sustained TSLP production by keratinocytes, driving skin itching, Th2 inflammation, and abnormal keratinocyte proliferation. Anti-TSLP therapies like Tezepelumab have also shown significant efficacy in this field.

Chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis: TSLP plays a key role in local inflammation in these diseases and is an important therapeutic target.

2. Tumor Immunology (Complex Role)

Promoting tumor progression: In many solid tumors, TSLP produced by tumor cells or tumor-associated fibroblasts can promote a type 2 inflammatory microenvironment, recruiting and activating immunosuppressive cells (e.g., M2 macrophages, Tregs), thereby suppressing anti-tumor immunity and promoting tumor growth and metastasis.

Potential anti-tumor effects: In certain hematologic malignancies (e.g., acute lymphoblastic leukemia) or specific contexts, TSLP may indirectly enhance anti-tumor T-cell responses by activating DCs, but its primary role is typically pro-tumorigenic.

3. Fibrotic Diseases

Pulmonary fibrosis, skin fibrosis: TSLP-driven type 2 cytokines (e.g., IL-13) are key factors promoting fibroblast activation and extracellular matrix deposition, contributing to organ fibrosis.

4. Gut Homeostasis and Inflammation

In the gut, TSLP has dual functions: during helminth infections, it drives protective type 2 immunity; in homeostasis, TSLP produced by intestinal epithelial cells may promote immune tolerance to food antigens and commensal bacteria by modulating DC function. Dysregulation of this function may contribute to inflammatory bowel disease.

IV. Future Prospects: From Upstream Targets to Precision Immune Modulation

As the "master switch" of type 2 inflammation, the success of TSLP-targeted therapies has opened new avenues for disease intervention, with future directions focusing on more precise and broader applications.

Expanding Therapeutic Frontiers:

Continued exploration of anti-TSLP therapies in other Th2/eosinophil-related diseases, such as chronic spontaneous urticaria and specific types of connective tissue disease-associated interstitial lung disease.

Developing Novel Modulators and Delivery Systems:

Beyond systemic antibodies, developing localized formulations, such as improved topical agents for atopic dermatitis or inhaled formulations for asthma, to maximize local efficacy and minimize systemic effects.

Exploring small-molecule TSLP signaling inhibitors to provide oral treatment options.

Precision Medicine and Biomarkers:

Identifying biomarkers that more accurately predict responses to anti-TSLP therapy. While Tezepelumab is not dependent on eosinophil counts, exploring factors like TSLP levels, upstream injury signals, or specific genetic signatures may enable finer patient stratification.

Combination Therapy Strategies:

Investigating combinations of TSLP inhibitors with other targeted therapies, such as anti-IL-4Rα, anti-IL-5/5R, anti-IgE, or JAK inhibitors, to comprehensively suppress the type 2 inflammatory loop at multiple nodes for the most refractory patients.

Understanding and Leveraging Its Homeostatic Functions:

Further research into TSLP's role in maintaining immune tolerance in areas like the gut, exploring the potential of locally applying low-dose TSLP or agonists in specific contexts (e.g., graft-versus-host disease, autoimmune diseases) to promote immune tolerance.

Connecting Environmental Exposure and Disease Risk:

Using TSLP as a readout of epithelial responses to environmental stimuli, studying how factors like pollutants and microbes influence TSLP expression to modulate individual risks of allergy and inflammatory diseases, providing new insights for disease prevention.

Summary

TSLP His Tag protein is a "core probe" for studying epithelial barrier immunity, representing an alarm language—epithelial cells use it to report "breach of defense" to the immune system. Once this signal is emitted, it triggers a cascade of type 2 immune events like dominoes, from the initial "education" of dendritic cells to the ultimate allergic inflammation. From driving the wheezing of asthma and the itching of dermatitis to becoming the first successfully targeted upstream alarmin, spawning revolutionary drugs, the research journey of TSLP perfectly illustrates the path from fundamental biological discovery to breakthrough therapy translation. In the future, by more precisely modulating this alarm system—whether completely silencing its false alarms in chronic diseases or cautiously leveraging its mild signals in homeostasis—we will be able to more intelligently manage barrier immunity, offering more fundamental and lasting relief to millions of patients with allergic and inflammatory diseases.